Portal de Programas de Pós-Graduação (UFSJ)

SIGAA - Sistema Integrado de Gestão de Atividades Acadêmicas

PPGCS PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE PRÓ-REITORIA DE PESQUISA E PÓS-GRADUAÇÃO Phone: Not available E-mail: melinapinheiro@ufsj.edu.br http://www.ufsj.edu.br//ppgcs

Banca de DEFESA: CECILIA SILVA SANTOS

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : CECILIA SILVA SANTOS
DATE: 30/01/2024
TIME: 14:00
LOCAL: Videoconferência
TITLE:

Histone deacetylase inhibitors as therapeutic targets against breast cancer and malaria: Systematic review

KEY WORDS:

Breast cancer; Epigenetic; Histone deacetylase inhibitors; Antineoplastic Agents; Malaria; Antimalarials; Acetylation; HDAC; Histone deacetylase.

PAGES: 91
BIG AREA: Ciências da Saúde
AREA: Enfermagem
SUBÁREA: Enfermagem de Saúde Pública
SUMMARY:

There is a significant increase in the morbidity and mortality profile of breast cancer

worldwide. In relation to current clinical treatments, chemotherapy has been the main

therapeutic protocol used, but despite advances, treatments end up producing adverse

and cytotoxic effects, in addition to showing resistance to the use of chemotherapy

drugs and the consequent reduction of treatment effects. Another serious public health

problem in the world is malaria, one of the diseases with the greatest impact on

morbidity and mortality in the population of tropic and subtropical countries. It is known

about the difficulties in controlling the vector, the lack of an effective vaccine and the

treatment, in turn, is carried out through antimalarial medications. However, the

parasite has shown resistance to available drugs, causing great difficulty in controlling

the disease. Given this conjecture, it is essential to search for alternative

chemotherapy agents for cancer and new treatments for malaria, which have different

mechanisms of action than the drugs currently used, and which cause patients the

minimum possible side effects for both models. Drugs that act as inhibitors of histone

deacetylases have presented a promising class of chemotherapy drugs and

antiparasitic models. Therefore, this study analyze scientific evidence about the

activities of histone deacetylase inhibitors as possible therapeutic strategies for breast

cancer and malaria. This is a systematic literature review, which followed the guidelines

of the PRISMA instrument, its question constructed based on the PICO acromion. The

bibliographic search was carried out in PubMed, Scielo and VHL, using DeCS/MESH.

The search was carried out from January to July 2023. The studies included in the

review were original articles, full access, available in the databases, published between

2013 and 2023, in English, Portuguese and Spanish and which responded to the

guiding question. The selection of articles occurred independently by two reviewers

and disagreements were discussed and resolved by a third researcher. After defining

the included studies, they were categorized and discussed. 1537 articles were found

on the topic, after applying the filters, 678 remained. Afterwards, the title and abstract

were read, and 120 studies were selected for reading in full. Of these, 39 articles were

selected to carry out this work. Of these, 33 articles related to breast cancer and 13

articles related to malaria. The various articles demonstrate their effectiveness in the

studies carried out, most of which are ready for the next phase of testing, showing

themselves to be very promising. In view of the above, the studies allow us to

recommend the use of HDACIs as a choice for testing and evaluating new compounds

for the treatment of cancer and malaria, in addition to the need for test studies for both

diseases.

BANKING MEMBERS:
Externa ao Programa - 2614385 - FLAVIA DE OLIVEIRA
Externa à Instituição - GABRIELA GONÇALVES AMARAL - UEMG
Externa ao Programa - 3351249 - SILMARA NUNES ANDRADE

Notícia cadastrada em: 18/12/2023 13:02